Présentation de l'entreprise
Cardiff Oncology, Inc. operates as a clinical-stage biotechnology entity focused on the development of novel therapeutic agents for the treatment of various cancers within the United States market. The company functions within the Healthcare sector, specifically the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant research and development expenditures before potential commercialization. With a market capitalization of $106.65M and an annual revenue of $593,000, the organization maintains a very small operational scale supported by a workforce of 30 employees. The disparity between the substantial market capitalization and the minimal revenue generation indicates that the company's valuation is driven almost exclusively by the perceived potential of its pipeline assets rather than current commercial operations or cash flow generation.
Santé financière
The company reported a revenue of $593,000 for the trailing twelve months, yet it recorded a net income of $-45,876,000 and an EBITDA of $-48,596,000, highlighting a significant structural gap where operating costs and R&D expenses far exceed current sales proceeds. This deep loss relative to minimal revenue reveals a cost structure typical of early-stage biotechnology firms where capital is heavily invested in clinical trials and regulatory processes before product launch. Free cash flow stands at $-19,617,000, indicating a negative liquidity position where cash outflows from operations and investing activities exceed cash inflows, thereby limiting immediate financial flexibility without external financing. All three margins reflect this operational reality: a Gross Margin of 0.0%, an Operating Margin of -3221.0%, and a Profit Margin of 0.0%, suggesting that the company is not yet profitable on a per-unit basis and is burning cash rapidly. On the balance sheet, cash holdings of $58.30M provide a buffer against total debt of $832,000, resulting in a Debt to Equity ratio of 1.83 which suggests a leveraged position relative to equity but is manageable given the cash reserves. The Current Ratio of 3.67 indicates a robust short-term liquidity position, as current assets are more than three times current liabilities, providing ample coverage for immediate obligations. Return on Equity is -71.5% and Return on Assets is -38.5%, metrics that reveal management is currently generating negative returns on the capital deployed, consistent with the early clinical development stage of the business.
Évaluation de la valorisation
Valuation metrics present a complex picture due to the lack of earnings, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -2.23, implying that expected earnings are negative and the traditional earnings-based valuation models are not applicable at this stage. The Price to Book ratio stands at 2.35, indicating that the market values the company at 2.35 times its book value, which suggests a premium assigned to the intangible value of the drug candidates and intellectual property over the tangible assets recorded on the balance sheet. Alternative valuation metrics such as a Price to Sales ratio of 179.85 and an EV/EBITDA of -1.01 further demonstrate that the stock is priced based on future revenue potential and asset value rather than current profitability. The 52-week price range spans from a low of $1.48 to a high of $4.56, and the current trading price sits somewhere within this band, reflecting high volatility common in small-cap biotech equities. A Beta of 1.42 indicates that the stock is 42% more volatile than the broader market, meaning it will likely experience larger swings in price during periods of market stress or recovery compared to large-cap indices.
Growth & Income
Revenue growth year-over-year is recorded at 60.9%, while earnings growth is N/A due to the absence of positive earnings in the prior period for comparison. The absence of a positive earnings base makes it impossible to calculate a traditional earnings growth rate, but the revenue expansion suggests successful scaling of commercial activities or strategic partnerships. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available cash and potential future earnings are reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage companies aiming to bring Onvansertib to market before initiating any shareholder return programs. Overall, the growth and income profile is defined by aggressive revenue expansion coupled with zero current profitability and no dividend distribution, relying entirely on capital markets for funding future milestones.